LXR agonists display significant anti-diabetic activities in diabetic rodent models but are associated with the risk of hypertriglyceridemia and liver steatosis [18] while synthetic selective thyroid hormone (TH) receptor (TR) modulators (STRM) reduce dyslipidemia, obesity, fatty liver, and insulin resistance in preclinical animal models [19]. Here, INS is linked to obesity disorder.